



Contents lists available at [SciVerse ScienceDirect](#)

Clinical Biochemistry

journal homepage: www.elsevier.com/locate/clinbiochem



Letter to the Editor

EPCA-2: A highly specific serum marker for prostate cancer

In 2007, Leman et al. published an apparently highly-promising new prostate cancer biomarker, early prostate cancer antigen-2 (EPCA-2) [1]. In my letter to *Clinical Biochemistry* [2], I criticized this biomarker and concluded that this marker may represent false discovery. These authors have now retracted this paper [3], citing that their original findings may be unreliable.

References

- [1] Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Marigold L, et al. EPCA-2: a highly specific serum marker for prostate cancer. *Urology* 2007;69:714–20.
- [2] Diamandis EP. Point: EPCA-2: a promising new serum biomarker for prostatic carcinoma? *Clin Biochem* 2007;40:1437–9.

- [3] Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Marigold L, et al. Retracted: EPCA-2: a highly specific serum marker for prostate cancer. *Urology* 2012;79:490.

Eletherios P. Diamandis
Mount Sinai Hospital and University Health Network, Canada
Division of Clinical Biochemistry,
Department of Laboratory Medicine & Pathobiology,
University of Toronto, Canada
Mount Sinai Hospital,
Joseph & Wolf Lebovic Ctr., 60 Murray St [Box 32]; Flr 6 - Rm L6-201,
Toronto, ON, M5T 3L9, Canada.
Fax: +1 416 619 5521.

E-mail address: ediamandis@mtsina.on.ca

15 February 2012